1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study.
Saved in:
| Title: | 1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study. |
|---|---|
| Authors: | Ellebaek, E.1 (AUTHOR), Weichenthal, M.2 (AUTHOR), Gavrilova, I.3 (AUTHOR), Asher, N.4 (AUTHOR), Meier, F.5 (AUTHOR), von Wasielewski, I.6 (AUTHOR), Dujović, B.7 (AUTHOR), Šabarić, V.8 (AUTHOR), Duvancic, T.9 (AUTHOR), Soria Rivas, A.10 (AUTHOR), Gutierrez Sanz, L.11 (AUTHOR), Haanen, J.B.A.G.12 (AUTHOR), Svane, I.M.1 (AUTHOR), Mohr, P.13 (AUTHOR), Ascierto, P.A.14 (AUTHOR), Mangana, J.15 (AUTHOR), Rutkowski, P.16 (AUTHOR), Gogas, H.17 (AUTHOR), Bastholt, L.18 (AUTHOR), Schadendorf, D.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS976-S977. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2274 |
